Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment - Anacor Pharmaceuticals, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jun. 24, 2016 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|||||||
| Business Acquisition [Line Items] | ||||||||||
| Cash payments for acquisition, net of cash acquired | [1] | $ 0 | $ 1,000 | $ 18,368 | ||||||
| Goodwill | $ 53,411 | [2] | $ 55,952 | [2] | $ 54,449 | |||||
| Anacor [Member] | ||||||||||
| Business Acquisition [Line Items] | ||||||||||
| Business acquisition, per share in cash (in dollars per share) | $ 99.25 | |||||||||
| Payments to acquire businesses, cash portion | $ 4,900 | |||||||||
| Cash payments for acquisition, net of cash acquired | 4,500 | |||||||||
| Debt assumed | 698 | |||||||||
| Indefinite-lived intangible assets | 4,900 | |||||||||
| Goodwill | 646 | |||||||||
| Net deferred tax liabilities | 346 | |||||||||
| In Process Research and Development [Member] | Anacor [Member] | ||||||||||
| Business Acquisition [Line Items] | ||||||||||
| Intangible assets | $ 4,800 | |||||||||
| ||||||||||